UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research
Ruanjuan Zhan,1,* Yanan Liu,1,2,* Jun Wu,1,2 Yuxin Shen,1,2 Xinhao Xu,1,2 Guanyang Lin,1,2 Xiaocheng Chen1 1The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, Peo...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/uplc-msms-method-for-givinostat-in-rat-plasma-development-validation-i-peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841536293081710592 |
|---|---|
| author | Zhan R Liu Y Wu J Shen Y Xu X Lin G Chen X |
| author_facet | Zhan R Liu Y Wu J Shen Y Xu X Lin G Chen X |
| author_sort | Zhan R |
| collection | DOAJ |
| description | Ruanjuan Zhan,1,* Yanan Liu,1,2,* Jun Wu,1,2 Yuxin Shen,1,2 Xinhao Xu,1,2 Guanyang Lin,1,2 Xiaocheng Chen1 1The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, People’s Republic of China*These authors contributed equally to this workCorrespondence: Guanyang Lin; Xiaocheng Chen, Email 13867702133@163.com; cxcwzcn@139.comBackground: Givinostat, a potent histone deacetylase (HDAC) inhibitor, is promising for the treatment of relapsed leukemia and myeloma.Purpose: This study aimed to develop and verify a quick assay for the measurement of givinostat concentration using ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) with eliglustat as the internal standard (IS), establishing a basic pharmacokinetic profile for its pre-clinical application and metabolic stability in vitro.Methods: Sample preparation was performed via protein precipitation using acetonitrile. The analyte (givinostat) and IS were gradient eluted on a Waters ACQUITY UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm) with 0.1% formic acid (A) and acetonitrile (B) as the mobile-phase system. The multiple reaction monitoring (MRM) in positive ion mode was used to detect the mass transition pairs for givinostat and IS as follows: m/z 422.01→ 186.11 for givinostat, and m/z 405.40→ 84.10 for IS, respectively.Results: In the bioanalytical method, good linearity was observed between 2 and 4000 ng/mL (r2=0.998). The intra- and inter-day precisions (RSD%) were lower than 15%, with an accuracy (RE%) of 95.8%– 108.6%. The recovery exceeded 90%, and the matrix effect was within the range of 98.2%– 107.6%. Additionally, this method was successful in evaluating pharmacokinetics in rats after an oral dose of 10 mg/kg givinostat. Finally, in vitro results showed that givinostat had a slow intrinsic clearance (CLint) value of 14.92 μL/min/mg protein with a half-life (t1/2) value of 92.87 min.Conclusion: Givinostat was rapidly absorbed and cleared slowly in vivo, and it was confirmed by in vitro experiments. This study provides a potential reference for givinostat in clinical studies.Keywords: givinostat, UPLC-MS/MS, rat plasma, pharmacokinetic study, in vitro metabolic stability |
| format | Article |
| id | doaj-art-e4e1ac6c8e184f24b1077ef971474c11 |
| institution | Kabale University |
| issn | 1177-8881 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj-art-e4e1ac6c8e184f24b1077ef971474c112025-01-14T16:51:43ZengDove Medical PressDrug Design, Development and Therapy1177-88812025-01-01Volume 1921922899210UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability ResearchZhan RLiu YWu JShen YXu XLin GChen XRuanjuan Zhan,1,* Yanan Liu,1,2,* Jun Wu,1,2 Yuxin Shen,1,2 Xinhao Xu,1,2 Guanyang Lin,1,2 Xiaocheng Chen1 1The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, People’s Republic of China; 2School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, People’s Republic of China*These authors contributed equally to this workCorrespondence: Guanyang Lin; Xiaocheng Chen, Email 13867702133@163.com; cxcwzcn@139.comBackground: Givinostat, a potent histone deacetylase (HDAC) inhibitor, is promising for the treatment of relapsed leukemia and myeloma.Purpose: This study aimed to develop and verify a quick assay for the measurement of givinostat concentration using ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) with eliglustat as the internal standard (IS), establishing a basic pharmacokinetic profile for its pre-clinical application and metabolic stability in vitro.Methods: Sample preparation was performed via protein precipitation using acetonitrile. The analyte (givinostat) and IS were gradient eluted on a Waters ACQUITY UPLC BEH C18 column (1.7 μm, 2.1 × 50 mm) with 0.1% formic acid (A) and acetonitrile (B) as the mobile-phase system. The multiple reaction monitoring (MRM) in positive ion mode was used to detect the mass transition pairs for givinostat and IS as follows: m/z 422.01→ 186.11 for givinostat, and m/z 405.40→ 84.10 for IS, respectively.Results: In the bioanalytical method, good linearity was observed between 2 and 4000 ng/mL (r2=0.998). The intra- and inter-day precisions (RSD%) were lower than 15%, with an accuracy (RE%) of 95.8%– 108.6%. The recovery exceeded 90%, and the matrix effect was within the range of 98.2%– 107.6%. Additionally, this method was successful in evaluating pharmacokinetics in rats after an oral dose of 10 mg/kg givinostat. Finally, in vitro results showed that givinostat had a slow intrinsic clearance (CLint) value of 14.92 μL/min/mg protein with a half-life (t1/2) value of 92.87 min.Conclusion: Givinostat was rapidly absorbed and cleared slowly in vivo, and it was confirmed by in vitro experiments. This study provides a potential reference for givinostat in clinical studies.Keywords: givinostat, UPLC-MS/MS, rat plasma, pharmacokinetic study, in vitro metabolic stabilityhttps://www.dovepress.com/uplc-msms-method-for-givinostat-in-rat-plasma-development-validation-i-peer-reviewed-fulltext-article-DDDTgivinostatuplc-ms/msrat plasmapharmacokinetic studyvitro metabolic stability |
| spellingShingle | Zhan R Liu Y Wu J Shen Y Xu X Lin G Chen X UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research Drug Design, Development and Therapy givinostat uplc-ms/ms rat plasma pharmacokinetic study vitro metabolic stability |
| title | UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research |
| title_full | UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research |
| title_fullStr | UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research |
| title_full_unstemmed | UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research |
| title_short | UPLC-MS/MS Method for Givinostat in Rat Plasma: Development, Validation, in vivo Pharmacokinetics Study and in vitro Metabolic Stability Research |
| title_sort | uplc ms ms method for givinostat in rat plasma development validation in vivo pharmacokinetics study and in vitro metabolic stability research |
| topic | givinostat uplc-ms/ms rat plasma pharmacokinetic study vitro metabolic stability |
| url | https://www.dovepress.com/uplc-msms-method-for-givinostat-in-rat-plasma-development-validation-i-peer-reviewed-fulltext-article-DDDT |
| work_keys_str_mv | AT zhanr uplcmsmsmethodforgivinostatinratplasmadevelopmentvalidationinvivopharmacokineticsstudyandinvitrometabolicstabilityresearch AT liuy uplcmsmsmethodforgivinostatinratplasmadevelopmentvalidationinvivopharmacokineticsstudyandinvitrometabolicstabilityresearch AT wuj uplcmsmsmethodforgivinostatinratplasmadevelopmentvalidationinvivopharmacokineticsstudyandinvitrometabolicstabilityresearch AT sheny uplcmsmsmethodforgivinostatinratplasmadevelopmentvalidationinvivopharmacokineticsstudyandinvitrometabolicstabilityresearch AT xux uplcmsmsmethodforgivinostatinratplasmadevelopmentvalidationinvivopharmacokineticsstudyandinvitrometabolicstabilityresearch AT ling uplcmsmsmethodforgivinostatinratplasmadevelopmentvalidationinvivopharmacokineticsstudyandinvitrometabolicstabilityresearch AT chenx uplcmsmsmethodforgivinostatinratplasmadevelopmentvalidationinvivopharmacokineticsstudyandinvitrometabolicstabilityresearch |